Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the Company recently received notice from the FDA that the Phase 3 clinical study in early Parkinson’s patients may proceed. The …
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease Read More